ScreenerHero

ANNX Annexon, Inc.

NAS · US · Healthcare · Biotechnology · annexonbio.com
4.010USD-0.50%Mkt Cap: 760.21M $P/E: —

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibod…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap760.21M USD
Enterprise Value579.41M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-206.69M USD
Revenue/Share—
Last Price4.010 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees92
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.71
PEG—
EV/EBITDA-2.78
EV/Revenue—
P/S—
P/B3.78
EPS (TTM)-1.09
EPS (Forward)-1.09
52W Range
2.54032% of range7.180
52W High7.180 USD
52W Low2.540 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-97.66%
ROA-74.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-186.36M USD
CapEx (TTM)137.00K USD
FCF Margin—
FCF Yield-15.26%
Net Debt-184.59M USD
Net Debt/EBITDA0.89
Balance Sheet
Debt/Equity0.12
Current Ratio5.53
Quick Ratio5.44
Book Value/Sh1.07 USD
Cash/Share1.10 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.43 USD
Upside (mean)+284.8%
Target Range7.000 USD – 27.00 USD
7.000+284.8% to mean27.00
# Analysts7
Ownership
Shares Out.189.58M
Float163.76M
Insiders0.44%
Institutions103.07%
Short Interest
Short Ratio12.2d
Short % Float18.35%
Short % Out.17.34%
Shares Short32.87M
Short (prev mo.)32.58M
Technical
SMA 504.737 (-15.3%)
SMA 2005.353 (-25.1%)
Beta1.33
S&P 52W Chg16.45%
Avg Vol (30d)3.13M
Avg Vol (10d)3.45M
Technical Indicators
RSI (14)40.5
MACD-0.2015
MACD Signal-0.2484
MACD Hist.+0.0469
BB Upper4.535 USD
BB Middle4.093 USD
BB Lower3.650 USD
BB Width21.61%
ATR (14)0.2671 USD
Vol Ratio (20d)0.69x